Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24
|
作者：
Vogel, AM
Lennon, DR
Broadbent, R
Byrnes, CA
Grimwood, K
Mildenhall, L
Richardson, V
Rowley, S
机构：
[1] Univ Auckland, Wellington, New Zealand
[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand
[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand
[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand
来源：
JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期
关键词：
consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;
D O I：
10.1046/j.1440-1754.2002.00057.x
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.
引用
收藏
页码：550 / 554
页数：5
相关论文
共 50 条
  • [31] Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017
    Kim, Doyoung
    Saleem, Mahwesh
    Paes, Bosco
    Mitchell, Ian
    Lanctot, Krista L.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (06) : 980 - 986
  • [32] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (07):
  • [33] Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease -: who should receive it?
    Sunnegårdh, J
    ACTA PAEDIATRICA, 2006, 95 (04) : 388 - 390
  • [34] Clinical consensus on respiratory syncytial virus (RSV) infection prophylaxis and the use of palivizumab in paediatric cardiology
    Medrano Lopez, C.
    Garcia-Guereta, L.
    Fernandez Pineda, L.
    Malo Concepcion, P.
    Maroto Alvaro, E.
    Santos de Soto, J.
    Lirio Casero, J.
    Suarez Cabrera, P.
    Caballero Martinez, F.
    ANALES DE PEDIATRIA, 2010, 72 (06): : 432 - 432
  • [35] Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma
    Carroll, Kecia N.
    Gebretsadik, Tebeb
    Escobar, Gabriel J.
    Wu, Pingsheng
    Li, Sherian Xu
    Walsh, Eileen M.
    Mitchel, Ed
    Sloan, Chantel D.
    Dupont, William D.
    Hartert, Tina V.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (01) : 66 - +
  • [36] Palivizumab for the prevention of respiratory syncytial virus infection
    Rogovik, Alexander L.
    Carleton, Bruce
    Solimano, Alfonso
    Goldman, Ran
    CANADIAN FAMILY PHYSICIAN, 2010, 56 (08) : 769 - 772
  • [37] Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria
    Resch, Bernhard
    Sommer, Constanze
    Nuijten, Mark J. C.
    Seidinger, Susanne
    Walter, Evelyn
    Schoellbauer, Vera
    Mueller, Wilhelm D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (01) : E1 - E8
  • [38] Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort
    Clark, SJ
    Beresford, MW
    Subhedar, NV
    Shaw, NJ
    ARCHIVES OF DISEASE IN CHILDHOOD, 2000, 83 (04) : 313 - 316
  • [39] Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
    Olchanski, Natalia
    Hansen, Ryan N.
    Pope, Elle
    D'Cruz, Brittany
    Fergie, Jaime
    Goldstein, Mitchell
    Krilov, Leonard R.
    McLaurin, Kimmie K.
    Nabrit-Stephens, Barbara
    Oster, Gerald
    Schaecher, Kenneth
    Shaya, Fadia T.
    Neumann, Peter J.
    Sullivan, Sean D.
    OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (03):
  • [40] Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease
    Pignotti, Maria Serenella
    Leo, Maria Carmela
    Pugi, Alessandra
    De Masi, Salvatore
    Biermann, Klaus Peter
    Galli, Luisa
    Rosati, Giovanni Vitali
    Buonocore, Giuseppe
    Mugelli, Alessandro
    Dani, Carlo
    Lucenteforte, Ersilia
    Bellini, Francesca
    Donzelli, Giampaolo
    PEDIATRIC PULMONOLOGY, 2016, 51 (10) : 1088 - 1096
12345